Results 41 to 50 of about 121,016 (287)

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

open access: yesNature Communications, 2021
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented ...
Michael S. Hwang   +21 more
doaj   +1 more source

Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance

open access: yesFrontiers in Immunology, 2021
Chimeric antigen receptor (CAR) transduced T cells have significantly improved cancer immunotherapy. Similarly, engineering regulatory T cells (Treg) with specific receptors to endow specificity and increase efficacy of Tregs holds great promise for ...
David W. Scott
doaj   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

open access: yes, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A.   +5 more
core   +2 more sources

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

open access: yes, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola   +3 more
core   +3 more sources

Chimeric Antigen Receptor beyond CAR-T Cells [PDF]

open access: yesCancers, 2021
Chimeric antigen receptors (CAR) are genetically engineered receptors that can recognise specific antigens and subsequently activate downstream signalling. Human T cells engineered to express a CAR, also known as CAR-T cells, can target a specific tumour antigen on the cell surface to mediate a cytotoxic response against the tumour.
Vicky Mengfei Qin   +3 more
openaire   +3 more sources

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

open access: yesActa Pharmaceutica Sinica B, 2018
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao   +4 more
doaj   +1 more source

Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV

open access: yesMolecular Therapy: Methods & Clinical Development, 2020
Human immunodeficiency virus (HIV) is an attractive target for chimeric antigen receptor (CAR) therapy. CAR T cells have proved remarkably potent in targeted killing of cancer cells, and we surmised that CAR T cells could prove useful in eradicating HIV ...
Ryan Z. Urak   +8 more
doaj   +1 more source

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity

open access: yesCells, 2021
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj   +1 more source

Gene modification strategies for next-generation CAR T cells against solid cancers

open access: yesJournal of Hematology & Oncology, 2020
Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies.
Yonggui Tian   +3 more
doaj   +1 more source

Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting

open access: yesNature Communications, 2023
Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.
Elisa Ruffo   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy